PhotonPharma’s Innocell involves sampling a patient’s tumor cells, inactivating them so that they are unable to replicate, then administering them back to the patient.
Startup
09/152021
09/092021
For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.
09/032021
Pulmonary arterial hypertension (PAH) affects 200, 000 people annually and there is no cure for this condition. Researchers at Indiana University and University of Illinois at Chicago, have identified a potential drug for curing PAH.
09/032021
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortalities of all malignancies, with aggressive biology, resistance to therapeutic agents, and a mere 5-year survival of 8-9%.
08/112021
SVC112 is a late-preclinical stage asset with potent single agent activity in genetically-defined models of salivary gland cancer, a neglected and orphan disease with no approved targeted or immunotherapy agents.
06/152021
ProGel is a platform technology with a diverse spectrum of drug payloads, such as steroids, statins, antioxidants, opioids, chemotherapeutics, and hormones. Ensign Pharmaceutical’s initial product focuses on managing osteoarthritis pain, incorporating a potent steroid, dexamethasone, into the formulation.